Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02141971 · ClinicalTrials.gov registry record
Down Syndrome Biomarker Initiative (DSBI)
A clinical trial of Alzheimers Disease and Down Syndrome, sponsored by Michael Rafii.
- Completed
- Registry status
- 12
- Enrollment target
- 1
- Study location
NCT02141971: Completed study of Alzheimers Disease and Down Syndrome, sponsored by Michael Rafii.
NCT02141971 is a study of Alzheimers Disease and Down Syndrome that has completed, run by Michael Rafii. The registered enrollment target is 12 participants, below the 3,926-participant average among 147 other Alzheimers Disease trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02141971, a study of Alzheimers Disease and Down Syndrome, has completed, sponsored by Michael Rafii.
- COMPLETED
- Registry status
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
Non-randomized natural history study involving 12 subjects with Down Syndrome, who are aged 30-60 years old. This study will observe 3 different groups: four non-demented subjects between ages 30-40 years old, four non-demented subjects between ages 40-50 years old, and four demented subjects 50-60 years old. Currently available longitudinal data in DS suggest a high rate of transition to dementia from the late 40s through the early 50s of these individuals. This, together with the universal presence of plaques in DS by their mid 40s makes this age range ideal for studying the development of AD.
Conditions Studied
Study Locations (1)
California
- University of California, San Diego - La Jolla
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2013-06-01 |
| Est. Completion | 2017-04-15 |
What the finished NCT02141971 record still lists
NCT02141971 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 3,926-participant average among 147 other Alzheimers Disease trials with a reported enrollment target (100% lower).
The record links to 2 conditions, with Alzheimers Disease appearing as the primary indexed condition, and to 0 interventions.
NCT02141971 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT02141971 about?
NCT02141971 is a clinical study titled "Down Syndrome Biomarker Initiative (DSBI)". Non-randomized natural history study involving 12 subjects with Down Syndrome, who are aged 30-60 years old. This study will observe 3 different groups: four non-demented subjects between ages 30-40 years old, four non-demented subjects between ages 40-50 years old, and four demented subjects 50-60 ...
What is the current status of trial NCT02141971?
This trial is currently completed. The enrollment target is 12 participants. The study started on 2013-06-01. Estimated completion is 2017-04-15.
What conditions does trial NCT02141971 study?
This clinical trial studies the following conditions: Alzheimers Disease, Down Syndrome.
Who is sponsoring clinical trial NCT02141971?
This trial is sponsored by Michael Rafii, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02141971 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimers Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02141971's enrollment target sits among peer trials
12 139th of 147 higher than 6 of 147 other Alzheimers Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Alzheimers Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
RECRUITING · Phase 3
-
Assessment of Foralumab Safety and Modulation of Microglial Activation in Alzheimer's Disease
RECRUITING · Phase 2
-
University of Central Florida Music Study
RECRUITING · NA
-
A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
RECRUITING · Phase 2
-
A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
RECRUITING · Phase 3
-
Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI